UCSF Medical Center Benioff Children's Hospital
Welcome,         Profile    Billing    Logout  
 4 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rosenthal, Philip
NCT06165341: Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

Recruiting
3
50
Europe, Canada, US
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo
Takeda
Alpha1-Antitrypsin Deficiency
08/28
08/28
NCT05677971: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Recruiting
3
160
Europe, Canada, US, RoW
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo, Sodium chloride
Takeda, Takeda Development Center Americas, Inc.
Alpha1-Antitrypsin Deficiency
03/27
03/29
RISE, NCT04729751 / 2020-004628-40: A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).

Completed
2
27
Europe, US, RoW
Maralixibat, Formerly LUM001 and SHP625
Mirum Pharmaceuticals, Inc.
Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome, Cholestatic Liver Disease
12/24
12/24
TRIUMPH, NCT04862221: TReatment for ImmUne Mediated PathopHysiology

Recruiting
2
163
US
High-dose methylprednisolone, Solu-Medrol, Equine anti-thymocyte globulin, ATGAM, Prednisolone, 15 mg/mL oral solution National Drug Code: 62135-250-37, Placebo for prednisolone, Placebo for infusions, 0.9% Sodium chloride, Diphenhydramine, Benadryl, Methylprednisolone
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Ann & Robert H Lurie Children's Hospital of Chicago
Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
01/26
01/27
DRUMARS, NCT04969185: Association Between Drug Levels, Malaria, and Antimalarial Resistance in the Setting of Seasonal Malaria Chemoprevention

Completed
N/A
310
RoW
University of California, San Francisco, Institut de Recherche en Sciences de la Sante, Burkina Faso
Malaria,Falciparum
11/21
05/23
Langlois, Camille
RISE, NCT04729751 / 2020-004628-40: A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).

Completed
2
27
Europe, US, RoW
Maralixibat, Formerly LUM001 and SHP625
Mirum Pharmaceuticals, Inc.
Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome, Cholestatic Liver Disease
12/24
12/24
NCT05272319: Genetic Collection Protocol

Recruiting
N/A
2230
Canada, US
Arbor Research Collaborative for Health
Liver Diseases
05/29
05/29

Download Options